Surgery after combination therapy with a tyrosine kinase inhibitor and anti-PD-1 antibody in sarcomatoid hepatocellular carcinoma: case report and literature review

IntroductionAlthough surgery is the preferred treatment for sarcomatoid hepatocellular carcinoma (SHC), the prognosis remains considerably poor due to early postoperative recurrence and metastasis. Reports on surgery after combined treatment with a tyrosine kinase inhibitor and anti-programmed cell...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Bin Liang, Tao Huang, Shao-Lei Kuang, Guang-Yuan Xie, Tian-Qi Liu, Yuan-Yuan Chen
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2023-10-01
Serija:	Frontiers in Oncology
Teme:	sarcomatoid hepatocellular carcinoma anti-angiogenic therapy anti-PD-1 antibody surgery combination therapy
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1212013/full
Oznake:	Označite Brez oznak, prvi označite!